Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — ASCO 2021

141 slides from Daiichi Sankyo's conference presentation, Jun 8, 2021

  1. Slide 1: ASCO 2021 Highlights

    ASCO 2021 Highlights DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa

  3. Slide 3: Progress since ASCO 2020

    Progress since ASCO 2020 EnhertuⓇ Dato-DXd HER3-DXd Strategic alliance with AZ delivering: ◆ Formed strategic alliance with AZ ◆ Strong market introduction/penetration ◆ Accelerating clinical development through ◆ Initiated NSCLC 3L pivotal trial aiming for ➢ Addition of launched countries for the a

  4. Slide 4: 5-Year Business Plan (FY2021-FY2025) for Sustainable Growth

    5-Year Business Plan (FY2021-FY2025) for Sustainable Growth Under ESG management, we will realize our 2025 Vision, Global Pharma Innovator with Competitive Advantage in Oncology, 2030 Vision and will shift to further growth toward our 2030 Vision Innovative Global Healthcare Company Contributing to

  5. Slide 5: Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025)

    Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025) Realize 2025 Vision and Shift to Further Growth Profit growth for current Identify and build Create shared value Maximize 3ADCs business and products pillars for further growth with stakeholders ◆ Maximize ENHERTU and ◆ Maximize Lixiana

  6. Slide 6: Cash Allocation for the 5-Year Business Plan

    Cash Allocation for the 5-Year Business Plan (FY2021-FY2025) Prioritize R&D and capital investments for 3ADCs and pay dividends taking account of profit growth Image for cash allocation R&D Investment for Growth Expense Prioritized investment for 3ADCs Operating Source for approx. Cash Flow cash all

  7. Slide 7: Financial Targets for the 5-Year Business Plan

    Financial Targets for the 5-Year Business Plan (FY2021-FY2025) Achieve significant revenue/profit growth ◆Revenue after investment for 3ADCs, and shift to a new stage for realizing 2030 vision 1.6 Tr JPY ➢ Oncology > 600.0 Bn JPY Revenue 960.0 Bn JPY ◆ Operating Profit* ratio 303.0 before R&D expens

  8. Slide 8: Focusing on the 2030 Vision and beyond

    Focusing on the 2030 Vision and beyond Selection of post Research activities taking DXd-ADC advantage of our Identifying modalities strength in cutting-edge growth science and technology drivers following Steady global Maximizing 3ADCs development bringing 3ADCs Sustainable promising products Growth

  9. Slide 9: Leading Daiichi Sankyo to a New Phase

    Leading Daiichi Sankyo to a New Phase 9

  10. Slide 10: ASCO 2021 Highlights

    ASCO 2021 Highlights DAIICHI SANKYO CO., LTD. Ken Takeshita, MD Global Head of R&D June 8, 2021 10

  11. Slide 11: Agenda

    Agenda 1 Introduction 2 ENHERTU®: New data & development plan 3 Dato-DXd: New data & development plan 4 HER3-DXd: New data & development plan 5 Future news flow 11

  12. Slide 12: My Educational & Professional History

    My Educational & Professional History Led full-scale global drug development programs across multiple tumor types panitumumab axi-cel romidepsin brexu-cel lenalidomide 12

  13. Slide 13: Why Daiichi Sankyo Became My Destination

    Why Daiichi Sankyo Became My Destination What I saw from the outside, looking in… • Very strong internal research • Courage to change – ➢Cardiovascular to oncology ➢Japan focus to global focus • Early successes in regulatory approvals 13

  14. Slide 14: My view and vision on our R&D

    My view and vision on our R&D To be a true global pharmaceutical company… Optimize the organization and cultivate human resources globally ◆ Competitiveness ➢Build upon our strengths to continually enhance our Science & Technology beyond 3ADCs • Cutting-edge science: next generation ADCs, mRNA, AAV,

  15. Slide 15: Daiichi Sankyo R&D Strategy

    Daiichi Sankyo R&D Strategy ◆ 3 and Alpha strategy ➢ Prioritize investment and resource allocation to 3ADCs ➢ Alpha focuses on changing SOCs 3ADCs & Alpha Specialty ENHERTU® Dato-DXd HER3-DXd Oncology Vaccine Medicine Swift expansion into broader cancer Identify competitive assets using types & trea

  16. Slide 16: Our goals for ENHERTU

    Our goals for ENHERTU® Transform the treatment for HER2 targetable tumors ASCO 2021 data HER2 Establish ENHERTU® as the new SOC in positive metastatic & early BC BEGONIA study Initial results of ENHERTU®+durvalumab BC - Build on unprecedented data in HER2 positive - Exploration in HER2 low/HR- popul

  17. Slide 17: Our goals for Dato-DXd

    Our goals for Dato-DXd Establish the position of Best-in-Class TROP2-directed ADC ASCO 2021 data Establish Dato-DXd as the First & Best-in-Class TROP2 ADC for NSCLC TROPION-PanTumor01 study Dose analysis of NSCLC cohort NSCLC - Introduce Dato-DXd as a key monotherapy for Supporting pivotal patients

  18. Slide 18: Our goals for HER3-DXd

    Our goals for HER3-DXd Establish the position of First-in-Class HER3-directed ADC ASCO 2021 data Establish HER3-DXd as the First-in-Class ADC for EGFR-mutated NSCLC with diverse Ph1 study NSCLC mechanisms of resistance to EGFR TKIs Updated data with a longer - Aim for fast to market in monotherapy &

  19. Slide 19: Agenda

    Agenda 1 Introduction 2 ENHERTU®: New data & development plan 3 Dato-DXd: New data & development plan 4 HER3-DXd: New data & development plan 5 Future news flow 19

  20. Slide 20: T-DXd in HER2-expressing Metastatic Colorectal Cancer: DESTINY-CRC01 Final Results

    Trastuzumab Deruxtecan (T-DXd; DS-8201) in Patients With HER2-expressing Metastatic Colorectal Cancer: Final Results From a Phase 2, Multicenter, Open-label Study (DESTINY-CRC01) Takayuki Yoshino; National Cancer Center Hospital East, Kashiwa, Japan June 7, 2021 Additional authors: Maria Di Bartolom

  21. Slide 21: DESTINY-CRC01 Study Design

    DESTINY-CRC01 Study Design An open-label, multicenter, phase 2 study (NCT03384940) 6.4 mg/kg dose of T-DXd administered Q3W (all cohorts) Cohort A: HER2 Positive Patients (IHC3+ or IHC2+/ISH+) Primary endpoint • ORRb (cohort A) Primary analysis • Unresectable and/or metastatic CRC n = 53 (Data cutof

  22. Slide 22: Efficacy Results

    Efficacy Results ASCO2021 22

  23. Slide 23: Progression-Free and Overall Survival

    Progression-Free and Overall Survival ASCO2021 23

  24. Slide 24: TEAEs in ≥20% of Patients

    TEAEs in ≥20% of Patients ASCO2021 24

  25. Slide 25: AEs of Special Interest: Interstitial Lung Disease

    AEs of Special Interest: Interstitial Lung Disease All Patients (N=86) n (%) Adjudicated drug-related ILDs: Grade 1 0 • Median time to adjudicated onset was 61.0 days (range, 9-165 Grade 2 4 (4.7) days) Grade 3 1 (1.2) • 8 of 8 patients received corticosteroids Grade 4 0 • 4 patients with grade 2 re

  26. Slide 26: DESTINY-CRC02 Study Design

    DESTINY-CRC02 Study Design A randomized, 2-arm, 2-stage, phase 2, multicenter global study (NCT04744831) STAGE 1a STAGE 2 Arm 1: T-DXd T-DXd 5.4 mg/kg Patients with HER2-overexpressing Planned: 5.4 mg/kg Q3W Q3W (IHC3+ or IHC2+/ISH+)b N = 120 n = 40 n = 40 unresectable, recurrent, R 1:1 Arm 2: or mC

  27. Slide 27: BEGONIA: Durvalumab Combinations in TNBC, Arm 6

    BEGONIA: PHASE 1B/2 STUDY OF DURVALUMAB (D) COMBINATIONS IN LOCALLY ADVANCED/METASTATIC TRIPLE-NEGATIVE BREAST CANCER: INITIAL RESULTS FROM ARM 6, D + TRASTUZUMAB DERUXTECAN (T-DXD) Peter Schmid, Seock-Ah Im, Anne Armstrong, Yeon Hee Park, Wei-Pang Chung, Zbigniew Nowecki, Simon Lord, Piotr Wysocki,

  28. Slide 28: BEGONIA Study Design

    BEGONIA Study Design Eligibility Criteria: Additional Arm 6 Criteria: • Unresectable locally advanced or metastatic Stage IV TNBC • HER2-low-expressing (IHC 2+/ISH-, IHC 1+/ISH-, • No prior treatment for Stage IV TNBC or IHC 1+/ISH untested, per local testing), estrogen • ≥12 months since taxane the

  29. Slide 29: Arm 6: Safety Summary (N=21)

    Arm 6: Safety Summary (N=21) ASCO2021 29

  30. Slide 30: Arm 6: Best change from baseline of target tumor size

    Arm 6: Best change from baseline of target tumor size • Local testing of HER2 expression successfully identified patients with HER2 IHC1+ and HER2 IHC2+/ISH– tumors, who * benefit from this treatment combination. • In this small group of patients, responses were observed in both PD-L1–positive (conf

  31. Slide 31: Arm 6 Conclusions: Durvalumab + T-DXd

    Arm 6 Conclusions: Durvalumab + T-DXd • Shows promising early efficacy signal in 1L metastatic HER2-low/ER-negative/ PR-negative breast cancer: confirmed ORR 8/12 (66.7%) patients in the response evaluable set. – Responses were observed regardless of PD-L1 expression (5% cutoff). – Local HER2 testin

  32. Slide 32: Pooled Analysis of Drug-Related ILD in 8 T-DXd Studies

    AACR 2021 CT167 Pooled Analysis of Drug-Related Interstitial Lung Disease in 8 Single-Arm Trastuzumab Deruxtecan Studies Charles A. Powell,1 Shanu Modi,2 Hiroji Iwata,3 Shunji Takahashi,4 Egbert F. Smit,5 Salvatore Siena,6 Dwan-Ying Chang,7 Kun Nie,8 Amy Qin,9Jasmeet Singh,9 Corina Taitt,9 Sunil Ver

  33. Slide 33: Incidence of ILD

    AACR 2021 Incidence of ILD Adjudicated study drug-related ILD by tumor type and grade HER2+ Breast Colorectal All patients Cancer, 5.4 mg/kg Gastric cancer Lung cancer cancer n (%) (N=879) (n=245) (n=78) (n=148) (n=107) Grade 1 40 (4.6) 9 (3.7) 0 4 (2.7) 1 (0.9) Grade 2 68 (7.7) 21 (8.6) 4 (5.1) 8 (

  34. Slide 34: Kaplan-Meier analysis of time to first ILD event

    AACR 2021 Kaplan-Meier analysis of time to first ILD event The risk of all-grade ILD decreased after 12 months, as the cumulative probability of adjudicated drug- related ILD began to plateau at this point 0.7 0.6 Among the 139 patients who had ILD, 122 (88%) Cumulative probability had a first ILD e

  35. Slide 35: Updated guidelines (2019) for ILD monitoring and management

    Updated guidelines (2019) for ILD monitoring and AACR 2021 management in clinical trials STEP 1: Monitor STEP 2: Confirm STEP 3: Manage Suspected ILD Evaluations should include: Drug must be interrupted for any • High-resolution CT ILD events regardless of grade • Pulmonologist consultation (infecti

  36. Slide 36: Updated guidelines (2019) for ILD monitoring and management

    Updated guidelines (2019) for ILD monitoring and AACR 2021 management in clinical trials 36

  37. Slide 37: Studies and patients included in the pooled analysis

    AACR 2021 Studies and patients included in the pooled analysis Kubo guidelines first Toxicity management ILD adjudication referenced in clinical Safe Use guidelines implemented committee established protocols (1Q 2018) Campaign initiated (December 2019) (November 2017) (June 2019) N=879 DS8201-A-J10

  38. Slide 38: Incidence of ILD after implementation of toxicity management guidelines

    Incidence of ILD after implementation of toxicity AACR 2021 management guidelines Updated toxicity management guidelines implemented (December 2019) Incidence of ILD over time 2016 2017 2018 2019 2020 (n=74) (n=168) (n=569) (n=179) (n=160) Any Grade ILD, n (%) 18 (24.3) 33 (19.6) 87 (15.3) 28 (15.6)

  39. Slide 39: ENHERTU: Clinical Development Plan | Breast cancer

    ENHERTU®: Clinical Development Plan | Breast cancer As of June 2021 FY2020 FY2021 FY2022 Planning Metastatic DESTINY-Breast01 completed 3L~ DESTINY-Breast02 monotherapy vs PC Metastatic DESTINY-Breast03 monotherapy vs T-DM1 2L DESTINY-Breast07 combination (2L/1L) Ph1b/2 HER2 Positive Metastatic 1L D

  40. Slide 40: ENHERTU: Clinical Development Plan | Gastric cancer & NSCLC

    ENHERTU®: Clinical Development Plan | Gastric cancer & NSCLC As of June 2021 FY2020 FY2021 FY2022 Planning Advanced/ DESTINY-Gastric01 Metastatic 3L~ DESTINY-Gastric02 monotherapy - West HER2 Advanced/ Gastric DESTINY-Gastric04 mono vs ramucirumab+paclitaxel Positive Metastatic 2L DESTINY-Gastric03

  41. Slide 41: ENHERTU: Clinical Development Plan | CRC & other tumors

    ENHERTU®: Clinical Development Plan | CRC & other tumors As of June 2021 FY2020 FY2021 FY2022 Planning Metastatic DESTINY-CRC01 monotherapy DESTINY-CRC02 monotherapy 3L HER2 Metastatic CRC Express Phase 3 2L ing Metastatic Phase 3 1L Nivolumab combination (breast, bladder) HER2 Metastatic Other Pemb

  42. Slide 42: ENHERTU: Key data readout

    ENHERTU®: Key data readout DESTINY-Breast02 | HER2 positive mBC • Event-driven primary analysis, vs standard of care projected FY2022 Q2 DESTINY-Breast03 | HER2 positive mBC • Event-driven interim analysis, vs T-DM1 projected FY2021 Q2 DESTINY-Breast04 | HER2 low mBC • Event-driven primary analysis,

  43. Slide 43: ENHERTU: Recently started & upcoming pivotal studies

    ENHERTU®: Recently started & upcoming pivotal studies DESTINY-Breast09 | • Ph3 study in 1st line advanced/metastatic Initiated in HER2 positive mBC HER2 positive breast cancer Jun 2021 vs THP DESTINY-Gastric04 | • Ph3 study in 2nd line advanced/metastatic Planned HER2 positive mGC HER2 positive gast

  44. Slide 44: Agenda

    Agenda 1 Introduction 2 ENHERTU®: New data & development plan 3 Dato-DXd: New data & development plan 4 HER3-DXd: New data & development plan 5 Future news flow 44

  45. Slide 45: TROPION-PanTumor01: Dose Analysis of Dato-DXd in NSCLC

    TROPION-PanTumor01: Dose Analysis of the TROP2-Directed Antibody- Drug Conjugate Datopotamab Deruxtecan (Dato-DXd; DS-1062) for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Funda Meric-Bernstam,1 Alexander Spira,2 Aaron E. Lisberg,3 Jacob M. Sands,4 Noboru Yamamoto,5 Me

  46. Slide 46: TROPION-PanTumor01 study design

    TROPION-PanTumor01 study design ◆ Updated clinical efficacy and safety results for the NSCLC cohort (data cutoff, January 8, 2021) as well as pharmacometric analyses are presented herein ◆ Pharmacometric analyses, including population pharmacokinetics (PopPK) and exposure-response modeling, were con

  47. Slide 47: Safety results

    Safety results Overall Safety Summary Treatment-Emergent Adverse Events in ≥15% of Patients ILD, interstitial lung disease; TEAE, treatment-emergent adverse event. a All fatal TEAEs reported as drug-related were pulmonary events and therefore were adjudicated for ILD/pneumonitis by an independent, e

  48. Slide 48: Efficacy results

    Efficacy results Best Overall Response (BICR) Best Change in Sum of Diameters (BICR) BICR, blinded independent central review; CR, complete response; DCR, disease control rate; DOR, duration of response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PFS, progression-free

  49. Slide 49: Pharmacometric Analysis: Projected Probabilities in a Virtual Population

    Pharmacometric Analysis: Projected Probabilities in a Virtual Population A virtual population of N=200 patients per dose was created by random sampling of the patients in the TROPION-PanTumor01 study. The factors that affect pharmacokinetics (weight, baseline albumin, sex) were well balanced across

  50. Slide 50: Summary/Conclusions

    Summary/Conclusions ◆ Dato-DXd shows highly encouraging antitumor activity with a manageable safety profile in patients with advanced or metastatic NSCLC, although results are limited by immature and unequal duration of follow-up across doses ◆ Tumor responses were durable across doses, with a trend

  51. Slide 51: Dato-DXd for Triple-Negative Breast Cancer: Preliminary Results

    Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody Drug Conjugate, for Triple-Negative Breast Cancer: Preliminary Results from an Ongoing Phase 1 Trial Aditya Bardia,1 Dejan Juric,1 Toshio Shimizu,2 Anthony Tolcher,3 Raghad Karim,3 Alexander Spira,4 Toru Mukohara,5 Aaron E. Lisberg,6 Takah

  52. Slide 52: TROPION-PanTumor01 – TNBC Cohort

    TROPION-PanTumor01 (NCT03401385) – TNBC Cohort Phase 1, First-in-human, Dose Escalation and Expansion Study • Advanced/metastatic HR-/HER2- negative breast cancer (TNBC)a Primary objectives include: • Relapsed/progressed on standard Dato-DXd 6mg/kg • Safety, Tolerability treatment IV Q3W • Unselecte

  53. Slide 53: Majority of Patients Were Heavily Pretreated

    Majority of Patients Were Heavily Pretreated ESMO2021 53

  54. Slide 54: Dato-DXd Demonstrated a Manageable Safety Profile

    Dato-DXd Demonstrated a Manageable Safety Profile ESMO2021 54

  55. Slide 55: Manageable, Predominantly Nonhematologic AEs

    Manageable, Predominantly Nonhematologic AEs ESMO2021 55

  56. Slide 56: Antitumor Activity (by BICR)

    Antitumor Activity (by BICR) 100 6 mg/kg Change in SoD of target lesions over time, % 80 8 mg/kg 60 40 20 0 -20 -40 -60 -80 -100 1 2 3 4 Months BICR, blinded independent central review; CR, complete response; PD, progressive disease; PR, partial response; SoD, sum of diameters. a Includes response e

  57. Slide 57: Conclusions

    Conclusions • Dato-DXd demonstrated a manageable safety profile and no patients discontinued treatment due to adverse events • Emerging efficacy results showed antitumor activity in heavily pretreated patients with metastatic TNBC – ORR by BICR was 43% and disease control rate was 95% • Further stud

  58. Slide 58: Dato-DXd: Clinical Development Plan | NSCLC & breast cancer

    Dato-DXd: Clinical Development Plan | NSCLC & breast cancer As of June 2021 FY2020 FY2021 FY2022 Planning Advanced/ All comers TROPION-PanTumor01 Metastatic 2L~ Advanced/ TROPION-Lung01 monotherapy vs Docetaxel Metastatic 2L~ Without Advanced/ actionable Metastatic 2L NSCLC mutations TROPION-Lung02

  59. Slide 59: Dato-DXd: Recent update

    Dato-DXd: Recent update TROPION-PanTumor01 | • Opened HR+ BC cohort in Ph1 HR+ BC cohort • First subject dosed in Mar 2021 BEGONIA | TNBC • AstraZeneca-led Ph1b/2 study for 1L TNBC Combination with durvalumab • Arm 7 (Dato-DXd+durvalumab) newly added • First subject dosed in May 2021 59

  60. Slide 60: Agenda

    Agenda 1 Introduction 2 Enhertu: New data & development plan 3 Dato-DXd: New data & development plan 4 HER3-DXd: New data & development plan 5 Future news flow 60

  61. Slide 61: Efficacy and Safety of HER3-DXd in EGFR Inhibitor-Resistant EGFRm NSCLC

    EFFICACY AND SAFETY OF PATRITUMAB DERUXTECAN (HER3-DXd) IN EGFR INHIBITOR– RESISTANT, EGFR-MUTATED (EGFRm) NON-SMALL CELL LUNG CANCER (NSCLC) Pasi A. Jänne,1 Christina Baik,2 Wu-Chou Su,3 Melissa L. Johnson,4 Hidetoshi Hayashi,5 Makoto Nishio,6 Dong-Wan Kim,7 Marianna Koczywas,8 Kathryn Gold,9 Conor

  62. Slide 62: HER3-DXd: Ph1 study in advanced EGFR-mutated NSCLC

    HER3-DXd: Ph1 study in advanced EGFR-mutated NSCLC Dose escalationa Dose expansiona HER3-DXd IV Q3W (21-day cycles) Adenocarcinoma NSCLC with EGFR mutations; prior Locally 6.4 mg/kg (N=5) 1 5.6 mg/kg (N=45) EGFR TKI and platinum-based chemotherapy advanced/metastatic NSCLC with 5.6 mg/kg (N=12) Squa

  63. Slide 63: HER3-DXd Demonstrated Durable Antitumor Activity After EGFR TKI and PBC

    HER3-DXd Demonstrated Durable Antitumor Activity After Failure of EGFR TKI and Platinum-based Chemotherapy (PBC) HER3-DXd 5.6 mg/kg Outcomes (BICR per RECIST 1.1) Prior TKI, ± PBC Prior OSI, PBC Median Follow Up: 10.2 (range, 5.2-19.9) moa (N=57) (N=44) Confirmed ORR, % (95% CI) 39 (26-52) 39 (24-55

  64. Slide 64: Activity With Diverse Mechanisms of EGFR TKI Resistance

    HER3-DXd Demonstrated Activity in Patients With Diverse ASCO2021 Mechanisms of EGFR TKI Resistance Median Confirmed ORR 39% Duration of Response 6.9 months Median PFS 8.2 months 40 Confirmed BORa + Ongoing Best % change in SoD (BICR) 20 CR PR SD PD NE treatment 0 from baseline -20 + + + + + + + -40

  65. Slide 65: Durable Responses Regardless of Prior Treatments or Brain Metastases

    Durable Responses Observed Regardless of Prior Treatments or History of Brain Metastases Prior OSI Prior PBC History of CNS metastases Treatment was ongoing in 18/57 (32%) patients at the data cut-off Treatment Duration Ongoing Ongoing (post PD) Assessments/events​a First response (confirmed) PD PD

  66. Slide 66: Clinical Responses Across Baseline HER3 Expression

    Clinical Responses Were Observed Across the Spectrum of Baseline HER3 Expression • HER3 was expressed in all evaluable patients’ (43/57) tumorsa Responses were observed in patients • HER3 expression was not correlated with time with a wide range of since last EGFR TKI dose baseline HER3 membrane H-s

  67. Slide 67: HER3-DXd Manageable Safety Profile and Low Discontinuation Rate

    HER3-DXd Was Associated With a Manageable Safety Profile and a Low Rate of Discontinuations Due to Adverse Events TEAEs, n (%) 5.6 mg/kg All Doses Median treatment duration: 5.7 (range, 0.7-28.3) mo (N=57) (N=81) Any TEAE 57(100) 81 (100) TEAEs grade ≥3 in ≥5% of patients (N=81) Associated with trea

  68. Slide 68: HER3-DXd: Targeting the unmet medical need in EGFR-TKI resistant EGFRm NSCLC

    HER3-DXd: Targeting the unmet medical need in EGFR-TKI resistant EGFRm NSCLC Clinically meaningful, durable efficacy (ORR, 39%; median PFS, 8.2 months) Antitumor • Efficacy shown across EGFR TKI resistance mechanisms in a difficult to treat patient population activity • Antitumor activity observed a

  69. Slide 69: HER3-DXd: Clinical Development Plan | NSCLC & other tumors

    HER3-DXd: Clinical Development Plan | NSCLC & other tumors As of June 2021 FY2020 FY2021 FY2022 Planning Advanced/ Ph1 dose expansion Metastatic 3L~ HERTHENA-Lung01 monotherapy EGFR NSCLC Advanced/ mutated Metastatic 2L Osimertinib combination Ph1b Advanced/ Metastatic 1L CRC All comers Metastatic 3

  70. Slide 70: Agenda

    Agenda 1 Introduction 2 Enhertu: New data & development plan 3 Dato-DXd: New data & development plan 4 HER3-DXd: New data & development plan 5 Future news flow 70

  71. Slide 71: FY2021 News Flow

    FY2021 News Flow As of Jun 2021 Planned publications European Hematology Association (Jun 9-17) Key data readout NHL Ph1 DESTINY-Breast03: HER2 positive BC, 2L, Ph3 DS-3201 • FY2021 Q2 • ATL, PTCL data (oral) DESTINY-Lung01: HER2 positive/mutated NSCLC, 2L, Ph2 WCLC (Sep 8-14) ENHERTU® • FY2021 Q2 T

  72. Slide 72: Daiichi Sankyo will contribute to the enrichment of quality of life around the world

    Daiichi Sankyo will contribute to the enrichment of quality of life around the world 72

  73. Slide 73: Appendix

    Appendix 73

  74. Slide 74: T-DXd in HER2+ Gastric Cancer: DESTINY-Gastric01 Final OS

    Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with human epidermal growth factor receptor 2–positive advanced gastric cancer or gastroesophageal junction adenocarcinoma: final overall survival results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01) Kensei Yamaguch

  75. Slide 75: Background and Study Design

    Background and Study Design DESTINY-Gastric01 Study Design • T-DXd is an antibody–drug conjugate comprising an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a topoisomerase I inhibitor payload (DXd)1 approved in the United States and Japan for adult patients with advanced HER2+ gast

  76. Slide 76: Results: Overall Survival

    Results: Overall Survival Kaplan-Meier Analysis of Overall Survival As in the primary analysis (101 OS events; 54.0% maturity), in this updated analysis (133 OS events; 71.1% maturity), T-DXd showed superior antitumor activity compared to PC HR, hazard ratio; OS, overall survival; PC, physician’s ch

  77. Slide 77: Results: ORR and Other Efficacy Endpoints

    Results: ORR and Other Efficacy Endpoints T-DXd PC Overall Best Percentage Change from Baseline in Tumor Size for Individual n = 119 n = 56 Patients ORR (CR + PR) by ICR, n (%) a 61 (51.3) 8 (14.3) 95% CI, 41.9-60.5 95% CI, 6.4-26.2 P < 0.0001b CR 11 (9.2) 0 PR 50 (42.0) 8 (14.3) SD 42 (35.3) 27 (48

  78. Slide 78: Safety

    Safety TEAEs in ≥20% of Patients Treated with T-DXd • Grade ≥3 AEs occurred in 85.6% of T-DXd patients vs T-DXd PC Overall 56.5% with PC n = 125 n = 62 Grade Grade – The most common were decreased neutrophil Preferred Term, % Any 3 4 Any 3 4 count (51.2%, 24.2%), anemia (38.4%, 22.6%), Neutrophil co

  79. Slide 79: Conclusions

    Conclusions • With continued follow-up after the primary analysis, T-DXd demonstrated clinically meaningful OS benefit (~40% reduced risk of death) and clinically relevant improvement in ORR compared with PC standard chemotherapy in HER2+ advanced gastric or GEJ cancer • The overall safety profile o

  80. Slide 80: Unmet Clinical Need in HER2-Positive Metastatic CRC

    Unmet Clinical Need for Approved Targeted Therapies in HER2-Positive Metastatic CRC • HER2 overexpression in mCRC • CRC is the 3rd most common type of cancer and ≈25% of patients have metastatic CRC, of which around 2-3% of patients have HER2-amplified tumors • Current treatment options are fluoropy

  81. Slide 81: Baseline Characteristics

    Baseline Characteristics ASCO2021 DESTINY-CRC01 81

  82. Slide 82: Baseline Characteristics (cont)

    Baseline Characteristics (cont) ASCO2021 DESTINY-CRC01 82

  83. Slide 83: Prior Treatments

    Prior Treatments ASCO2021 DESTINY-CRC01 83

  84. Slide 84: Overall Safety Summary

    Overall Safety Summary ASCO2021 DESTINY-CRC01 84

  85. Slide 85: Change in Tumor Size in Cohort A

    Change in Tumor Size in Cohort A a4 patients from the full analysis set were excluded since 1 patient had no measurable target lesion and 3 patients HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization. had no postbaseline data. b1 patient from cohort

  86. Slide 86: Conclusions

    Conclusions • T-DXd monotherapy at the 6.4 mg/kg Q3W dose showed promising activity and durability with longer-term follow-up (additional 35.3 weeks from the primary analysis) in patients with HER2+ mCRC • For cohort A, confirmed ORR was 45.3% (95% CI, 31.6–59.6), mDOR was 7.0 months (95% CI, 5.8–9.

  87. Slide 87: Introduction

    Introduction ASCO2021 T-DXd: BEGONIA 87

  88. Slide 88: Methods

    Methods ASCO2021 T-DXd: BEGONIA 88

  89. Slide 89: Arm 1: Durvalumab + Paclitaxel

    ARM 1: Durvalumab + Paclitaxel ASCO2021 T-DXd: BEGONIA 89

  90. Slide 90: Arm 1: Patient Disposition and Characteristics (N=23)

    Arm 1: Patient Disposition and Characteristics (N=23) ASCO2021 T-DXd: BEGONIA 90

  91. Slide 91: Arm 1: Safety Summary (N=23)

    Arm 1: Safety Summary (N=23) ASCO2021 T-DXd: BEGONIA 91

  92. Slide 92: Arm 1: Safety Summary (N=23), cont’d

    Arm 1: Safety Summary (N=23), cont’d Grade 3/4 AEs Additional AE Details ASCO2021 T-DXd: BEGONIA 92

  93. Slide 93: Arm 1: Best change from baseline of target tumor size

    Arm 1: Best change from baseline of target tumor size • In this small population, responses occurred for both PD-L1–positive (confirmed ORR 6/7 [85.7%]) and PD-L1–negative (confirmed ORR 6/14 [42.9%]) groups * If the best percentage change from baseline of target lesions cannot be calculated due to

  94. Slide 94: Arm 1: Change from baseline in target tumor size over time

    Arm 1: Change from baseline in target tumor size over time • A total of 7/13 (53.8%) patients remained in response at the time of data cutoff ASCO2021 T-DXd: BEGONIA 94

  95. Slide 95: Arm 1: Treatment Exposure & Duration of Response

    Arm 1: Treatment Exposure & Duration of Response (N=23) ASCO2021 T-DXd: BEGONIA 95

  96. Slide 96: Arm 1 Conclusions: Durvalumab + Paclitaxel

    Arm 1 Conclusions: Durvalumab + Paclitaxel • Acceptable safety/tolerability profile and demonstrates a response rate (confirmed ORR 56.5%) consistent with published data for 1L TNBC IO/taxane combination studies. – This was also consistent for patients with positive PD-L1 expression. • Responses wer

  97. Slide 97: Arm 6: Change in target lesion & duration of treatment

    Arm 6: Change in target lesion & duration of treatment ASCO2021 T-DXd: BEGONIA 97

  98. Slide 98: Arm 6: Patient Disposition and Characteristics (N=21)

    Arm 6: Patient Disposition and Characteristics (N=21) • As of the data cutoff of March 2021, 21 patients received D+T- DXd with 19 still on treatment. • Median (range) follow-up time: 3.6 (0–9) months. ASCO2021 T-DXd: BEGONIA 98

  99. Slide 99: Arm 6: Safety Summary (N=21), cont’d

    Arm 6: Safety Summary (N=21), cont’d Grade 3/4 AEs Additional AE Details ASCO2021 T-DXd: BEGONIA 99

  100. Slide 100: T-DXd in HER2+ Breast Cancer With Brain Metastases: DESTINY-Breast01 Subgroup

    TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WITH BRAIN METASTASES: A SUBGROUP ANALYSIS OF THE DESTINY-BREAST01 TRIAL Guy Jerusalem,1 Yeon Hee Park,2 Toshinari Yamashita,3 Sara A. Hurvitz,4 Shanu Modi,5 Fabrice Andre,6 Ian E. Krop,7 Xavier Gonzalez,8 Peter S. Hall,9

  101. Slide 101: Background

    Background ▪ Here we describe a subgroup analysis from the ongoing DESTINY- Breast01 study, analyzing the efficacy of T-DXd in patients with a history of brain metastases Methods ▪ Patients with brain metastases who were treated, asymptomatic, and did not require therapy to control symptoms were eli

  102. Slide 102: Baseline Characteristics & Clinical Activity Outcomes

    Baseline Characteristics & Clinical Activity Outcomes ▪ Efficacy of T-DXd in the CNS subgroup was comparable to that of the overall population ▪ In the overall population, 4 of 184 (2.2%) patients had CNS progression events ▪ In the CNS subgroup, 2 of 24 (8.3%) patients had CNS progression events oc

  103. Slide 103: CNS Response

    CNS Response Best Response in Brain Lesions in Patients in the Example Brain Scans CNS Subgroup ▪ Of 24 patients in the CNS subgroup, 17 had brain lesions at baseline; data were available to evaluate responses in the brain for 15 of these 17 patients ▪ Of the 15 patients, 13 completed radiotherapy a

  104. Slide 104: CNS Response

    CNS Response Brain Lesion Measurements Over Time in Progression-Free Survival in the CNS Subgroup Patients in the CNS Subgroup (n=24) Change from baseline (%) 3 patients with reported baseline measurements had no change over time. PFS, progression-free survival. 2 patients with brain metastases at b

  105. Slide 105: Conclusions

    Conclusions ▪ T-DXd showed durable systemic disease control in patients with stable, treated brain metastases at baseline, with clinical outcomes similar to those of the overall population (as of the August 1, 2019, data cutoff) ▪ Of 17 patients with brain lesions at baseline, 41.2% (n=7) experience

  106. Slide 106: T-DXd in HER2-expressing Salivary Duct Carcinoma

    Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies Hideaki Bando1, Ichiro Kinoshita2, Shanu Modi3, Junji Tsurutani4, Yung-Jue Bang5, Hiroji Iwata1, Yuta Sato6, Shunsuke Nakatani6

  107. Slide 107: Background

    Background • In salivary duct carcinoma (SDC), 16%‒83% of patients are reported to show human epidermal growth factor receptor 2 (HER2) expression by immunohistochemistry (IHC) or HER2 amplification by in situ hybridization (ISH)/next-generation sequencing (NGS)1 • There are no established HER2-targ

  108. Slide 108: Methods

    Methods • DS8201-A-J101: first-in-human phase 1 study of T-DXd including patients with HER2-expressing SDC –Dose-escalation phase: T-DXd 5.4 and 6.4 mg/kg (every 3 weeks) was recommended for the dose-expansion phase of the study7 –Dose-expansion phase: T-DXd demonstrated promising activity and an ac

  109. Slide 109: Results

    Results • Of the 17 patients with HER2-expressing SDC, 8 and 9 patients were enrolled from DS8201-A-J101 and DS8201-A-A104, respectively (Table 1) • The cutoff date for the data analysis is 1 Aug 2019 for DS8201-A-J101 and 26 Sep 2018 for DS8201-A-A104 • At data cutoff, 41.2% of patients continued T

  110. Slide 110: Results (cont’d)

    Results (cont’d) Table 1. Demographics and baseline clinical characteristics Characteristic J101 (N=8) A104 (N=9) Pooled (N=17) Age, years, median (range) 51.5 (44–69) 58.0 (34–71) 57.0 (34–71) Sex, n (%) Male 6 (75.0) 9 (100.0) 15 (88.2) Female 2 (25.0) 0 (0.0) 2 (11.8) Race,a n (%) Asian 7 (87.5)

  111. Slide 111: Results (cont’d)

    Results (cont’d) Table 1. Demographics and baseline clinical characteristics (cont’d) Characteristic J101 (N=8) A104 (N=9) Pooled (N=17) HER2 expression (IHC),a n (%) 0 0 (0.0) 0 (0.0) 0 (0.0) 1+ 0 (0.0) 0 (0.0) 0 (0.0) 2+ 0 (0.0) 1 (11.1) 1 (5.9) 3+ 8 (100.0) 3 (33.3) 11 (64.7) Nonevaluable 0 (0.0)

  112. Slide 112: Results (cont’d)

    Results (cont’d) Table 1. Demographics and baseline clinical characteristics (cont’d) Characteristic J101 (N=8) A104 (N=9) Pooled (N=17) Site of primary disease, n (%) Parotid gland 4 (50.0) 2 (22.2) 6 (35.3) Submandibular gland 2 (25.0) 2 (22.2) 4 (23.5) Glandula sublingualis 0 (0.0) 1 (11.1) 1 (5.

  113. Slide 113: Results (cont’d)

    Results (cont’d) Table 2. Patient disposition J101 (N=8) A104 (N=9) Pooled (N=17) Duration of follow-up, months, 13.0 2.8 5.6 median (range) (4.4–34.8) (2.1–6.3) (2.1–34.8) Ongoing T-DXd, n (%) 1 (12.5) 6 (66.7) 7 (41.2) Discontinued T-DXd, n (%) 7 (87.5) 3 (33.3) 10 (58.8) Primary reason for discon

  114. Slide 114: Efficacy Results

    Efficacy Results • The confirmed overall response rate in the pooled analysis was 47.1% (95% confidence interval [CI], 23.0–72.2) (Table 3) • 15 patients had target lesions per RECIST version 1.1, of whom 93% (14/15) showed tumor shrinkage in 12 weeks post-baseline assessment (Figure 2) and one of c

  115. Slide 115: Efficacy Results (cont’d)

    Efficacy Results (cont’d) Table 3. Clinical activity outcomes J101 (N=8) A104 (N=9) Pooled (N=17) Best overall response (confirmed), n (%) CR 0 (0.0) 0 (0.0) 0 (0.0) PR 6 (75.0) 2 (22.2) 8 (47.1) SD 2 (25.0) 7 (77.8) 9 (52.9) PD 0 (0.0) 0 (0.0) 0 (0.0) NE 0 (0.0) 0 (0.0) 0 (0.0) Confirmed ORR, n (%)

  116. Slide 116: Efficacy Results (cont’d)

    Efficacy Results (cont’d) Table 3. Clinical activity outcomes (cont’d) J101 (N=8) A104 (N=9) Pooled (N=17) DOR, months, median [95% CI]a 12.9 [4.0–NE] NE [NE–NE] 12.9 [4.0–NE] Patients with events, n (%) 6 (75.0) 2 (22.2) 8 (47.1) Patients censored, n (%) 2 (33.3) 2 (100.0) 4 (50.0) Ongoing without

  117. Slide 117: Efficacy Results (cont’d)

    Efficacy Results (cont’d) Figure 2. Best percentage change in tumor size HER2 expression shown is based on central laboratory assessment. HER2 expression status at enrollment was determined via local assessment. The red line denotes a 30% reduction in tumor size. T-DXd Ph1: Subgroup Analysis ASCO202

  118. Slide 118: Efficacy Results (cont’d)

    Efficacy Results (cont’d) Figure 3. Case report: 69% (Lung left) or 67% (Lung right) regression of a metastatic lung lesion • 65-year-old man with IHC 2+/ISH negative (central assessment) for HER2 metastatic sublingual gland • 1 prior line of treatment, including bicalutamide and leuprorelin Baselin

  119. Slide 119: Safety Results

    Safety Results • Treatment-emergent adverse events (TEAEs) occurred in all 17 patients; 23.5% of patients discontinued treatment and 17.6% and 41.2% of patients experienced dose reduction and dose interruption, respectively, due to TEAEs (Table 4) • The most common grade ≥3 TEAEs (64.7%) were decrea

  120. Slide 120: Safety Results (cont’d)

    Safety Results (cont’d) Table 4. Safety summary n (%) Pooled (5.4 or 6.4 mg/kg) (N=17) All TEAEs 17 (100) Drug related 17 (100) TEAE grade ≥3 11 (64.7) Drug related 9 (52.9) Serious TEAEs 3 (17.6) Drug related 1 (5.9) TEAE associated with discontinuation 4 (23.5) Drug related 3 (17.6) TEAE associate

  121. Slide 121: Safety Results (cont’d)

    Safety Results (cont’d) Table 5. Common TEAEs (≥20%) and adjudicated drug-related ILD TEAEs (≥20%) Pooled (5.4 or 6.4 mg/kg) (N=17) n (%) All Grades Grade ≥3 Any TEAE 17 (100) 11 (64.7) Decreased appetite 15 (88.2) 1 (5.9) Nausea 15 (88.2) 0 (0.0) Neutrophil count decreaseda 13 (76.5) 8 (47.1) White

  122. Slide 122: Safety Results (cont’d)

    Safety Results (cont’d) Table 5. Common TEAEs (≥20%) and adjudicated drug-related ILD (cont’d) TEAEs (≥20%) Pooled (5.4 or 6.4 mg/kg) (N=17) n (%) All Grades Grade ≥3 Any TEAE 17 (100) 11 (64.7) Malaise 6 (35.3) 0 (0.0) Alopecia 6 (35.3) 0 (0.0) Anemiaa 5 (29.4) 2 (11.8) Cough 5 (29.4) 0 (0.0) Diarr

  123. Slide 123: Conclusions

    Conclusions • T-DXd 5.4 and 6.4 mg/kg showed promising antitumor activity in HER2- expressing SDC with durable responses • Confirmed objective response rate: 47.1% • Median duration of response: 12.9 months • Median progression-free survival: 14.1 months • The safety profile was generally consistent

  124. Slide 124: Background

    Background • T-DXd has been approved for use in patients with HER2-positive metastatic breast cancer that has progressed on ≥2 prior anti-HER2 therapies (US, EU, UK) or after chemotherapy (Japan) and in patients with HER2-positive metastatic gastric cancer who have received a prior trastuzumab-based

  125. Slide 125: Methods

    Methods Data as of 08 June 2020 were An independent adjudication A multivariate stepwise Cox pooled from 879 patients who committee retrospectively regression model was used to received ≥1 dose of T-DXd reviewed all potential ILD cases explore the association between monotherapy at 5.4, 6.4, 7.4, or

  126. Slide 126: Baseline characteristics and T-DXd treatment

    Baseline characteristics and T-DXd treatment Patients were heavily pretreated with advanced disease N=879 N=879 Age, median (range), years 58.0 (23-96) No. of prior regimens, median 5.0 (1-27) ≥ 65 years, n (%) 271 (30.8) (range) Female, n (%) 674 (76.7) T-DXd dose, n (%) Japanese, n (%) 364 (41.4)

  127. Slide 127: Investigator-assessed ILD onset date vs adjudication committee

    Investigator-assessed ILD onset date vs adjudication committee Adjudicated drug-related ILD events (n=148) Concordant, n (%) 72 (48.6%) Discordant, n (%) Earlier than the adjudication committee 5 (3.4%) Median difference (range), days 7.0 (1-44) Later than the adjudication committee 71 (48.0%) Media

  128. Slide 128: Summary of steroid use

    Summary of steroid use Systemic steroid use by grade of adjudicated drug-related ILD Events leading to Grade 2-4 Grade 5 No. of events 80 21 Events treated with systemic steroids, n (%) 48 (60.0) 16 (76.1) Defined as any systemic steroids initiated within 90 days of the adjudicated ILD onset date. S

  129. Slide 129: Assessment of factors potentially associated with ILD

    Assessment of factors potentially associated with ILD A stepwise multivariate Cox regression model evaluated the association of potential factors with the time to occurrence of any-grade ILD, and the following 6 were identified as factors of interest: • Patients treated in Japan vs non-Japan • Dose

  130. Slide 130: Conclusions

    Conclusions • T-DXd had shown significant antitumor activity in HER2-positive metastatic breast1 and gastric cancer,2 as well as other tumor types3 • The majority of independently adjudicated ILD cases (78%) were low grade • ILD risk may decrease after ≈12 months of treatment; longer follow-up is ne

  131. Slide 131: Patient Disposition

    Patient Disposition Due to later time of enrollment, follow-up was shorter for patients treated with the 4- and 6-mg/kg doses than the 8-mg/kg dose TROPION-PanTumor01 ASCO2021 (NSCLC) 131

  132. Slide 132: Patient Demographics and Baseline Characteristics

    Patient Demographics and Baseline Characteristics Baseline characteristics were generally balanced across dosing cohorts TROPION-PanTumor01 ASCO2021 (NSCLC) 132

  133. Slide 133: Efficacy: Change in Sum of Diameters for Target Lesions Over Time

    Efficacy: Change in Sum of Diameters for Target Lesions (BICR) Over Time Most responses were durable over time TROPION-PanTumor01 ASCO2021 (NSCLC) 133

  134. Slide 134: Broad Range of Resistance Mechanisms in EGFRm NSCLC

    Broad Range of Resistance Mechanisms in EGFRm NSCLC Following the Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy • Efficacy of EGFR TKI in EGFRm NSCLC has been established; however, the development of various resistance mechanisms commonly leads to disease progression1-2 • Platinum-based ch

  135. Slide 135: Patritumab Deruxtecan (HER3-DXd): Targeting HER3

    Patritumab Deruxtecan (HER3-DXd)—Targeting HER3 May Address Multiple EGFR TKI Resistance Mechanisms • HER3-DXd is an ADC with 3 components:1-6 HER3 is expressed in • A fully human anti-HER3 IgG1 mAb (patritumab), covalently linked to: 83% of NSCLC tumors7,a • A topoisomerase I inhibitor payload, an

  136. Slide 136: HER3-DXd Antitumor Activity by History of CNS Metastases

    HER3-DXd Antitumor Activity by History of CNS Metastases In Patients Previously Treated with an EGFR TKI and Platinum-based Chemotherapy History of Brain Metastases HER3-DXd 5.6 mg/kg (N=52)a Outcomes (BICR per RECIST 1.1) Median Follow Up: 9.6 (range, 5.2-19.9) moa Yes (N=25) No (N=27) Confirmed OR

  137. Slide 137: Early Clearance of EGFR Mutations in ctDNA and PFS

    Early Clearance of EGFR Ex19del or L858R Mutations in ctDNA is Associated With Favorable BOR and PFS Early clearance of ctDNA was defined as non-detectable plasma of either EGFR Ex19del or EGFR L858R at Week 3 or 6, where either mutation was detectable at baseline (evaluable in 40/57 patientsa) Conf

  138. Slide 138: ENHERTU: DESTINY-Breast09 Study

    ENHERTU®: DESTINY-Breast09 Study ENHERTU® with or without pertuzumab compared to taxane+ trastuzumab+pertuzumab in 1L HER2+ metastatic breast cancer ENHERTU® Pertuzumab placebo 1L HER2 positive Randomize ENHERTU® metastatic breast 1:1 Pertuzumab cancer Taxane Trastuzumab Pertuzumab Endpoints: PFS as

  139. Slide 139: ENHERTU: DESTINY-Gastric04 Study

    ENHERTU®: DESTINY-Gastric04 Study ENHERTU® vs ramucirumab+paclitaxel in 2L HER2+ metastatic gastric cancer ENHERTU® 2L HER2 positive Randomize metastatic gastric 1:1 cancer Ramucirumab + Paclitaxel Endpoints: OS as well as other endpoints Study start: FY2021 1H planned ClinicalTrials.gov Identifier:

  140. Slide 140: HER3-DXd: Significance and Future Direction

    HER3-DXd: Significance and Future Direction Clear medical need in a difficult to treat patient population • Salvage therapy is minimally effective, and offers short durations of efficacy (PFS, 2.8–3.2 months) Post-TKI • HER3-DXd offers clinically meaningful, durable efficacy in a heavily pretreated

  141. Slide 141: Contact address regarding this material

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1125 Email: DaiichiSankyoIR@daiichisankyo.co.jp 141

Daiichi Sankyo Company — ASCO 2021 on 6ix